International Journal of Antimicrobial Agents

Scope & Guideline

Advancing the Fight Against Antimicrobial Resistance

Introduction

Welcome to your portal for understanding International Journal of Antimicrobial Agents, featuring guidelines for its aims and scope. Our guidelines cover trending and emerging topics, identifying the forefront of research. Additionally, we track declining topics, offering insights into areas experiencing reduced scholarly attention. Key highlights include highly cited topics and recently published papers, curated within these guidelines to assist you in navigating influential academic dialogues.
LanguageEnglish
ISSN0924-8579
PublisherELSEVIER
Support Open AccessNo
CountryNetherlands
TypeJournal
Convergefrom 1991 to 2024
AbbreviationINT J ANTIMICROB AG / Int. J. Antimicrob. Agents
Frequency12 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressRADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS

Aims and Scopes

The International Journal of Antimicrobial Agents focuses on advancing the understanding of antimicrobial agents, their mechanisms of action, resistance patterns, and therapeutic applications. The journal aims to disseminate significant research findings that contribute to the field of infectious diseases and antimicrobial stewardship.
  1. Antimicrobial Resistance Research:
    The journal emphasizes studies on the mechanisms and epidemiology of antimicrobial resistance, particularly in common pathogens such as Escherichia coli, Klebsiella pneumoniae, and Staphylococcus aureus.
  2. Clinical Pharmacokinetics and Pharmacodynamics:
    Research focusing on the pharmacokinetics and pharmacodynamics of antimicrobial agents, aiming to optimize dosing regimens and improve therapeutic outcomes in various patient populations.
  3. Innovative Therapeutic Strategies:
    The journal publishes articles on novel therapeutic approaches, including combination therapies, new antimicrobial agents, and adjunct therapies to enhance the efficacy of existing treatments.
  4. Antimicrobial Stewardship:
    A focus on strategies to optimize the use of antimicrobials in clinical settings, including stewardship programs and guidelines for appropriate prescribing practices.
  5. Infection Control and Epidemiology:
    Research related to infection control practices, surveillance of antimicrobial resistance, and the impact of public health interventions on infection rates.
  6. Emerging Infectious Diseases:
    The journal addresses the challenges posed by emerging infectious diseases and the role of antimicrobial agents in their management.
The International Journal of Antimicrobial Agents has identified several trending and emerging themes in recent years, reflecting the evolving landscape of antimicrobial research and the pressing challenges posed by antimicrobial resistance.
  1. Machine Learning and Predictive Analytics:
    The application of machine learning algorithms to predict antimicrobial resistance patterns and optimize treatment regimens is gaining traction, highlighting the intersection of technology and clinical microbiology.
  2. Phage Therapy and Alternative Antimicrobials:
    Research on bacteriophage therapy and other alternative antimicrobial strategies is emerging as a promising area, particularly for multidrug-resistant infections.
  3. Personalized Medicine Approaches:
    There is an increasing emphasis on personalized medicine in infectious disease treatment, with studies focusing on tailoring antimicrobial therapy based on genetic, pharmacokinetic, and clinical factors.
  4. Global Surveillance and Epidemiology:
    The journal is seeing a rise in research related to global surveillance of antimicrobial resistance and the epidemiology of infectious diseases, driven by the need for comprehensive data to inform public health strategies.
  5. Antimicrobial Stewardship Innovations:
    Innovative approaches to antimicrobial stewardship, including new guidelines and educational interventions, are trending as healthcare systems seek to combat rising resistance rates.
  6. Impact of COVID-19 on Antimicrobial Use:
    Research examining the impact of the COVID-19 pandemic on antimicrobial prescribing patterns and resistance trends is becoming increasingly prominent, reflecting the ongoing global health crisis.

Declining or Waning

While the journal maintains a robust focus on various aspects of antimicrobial research, certain themes have shown a decline in prominence over recent years. These waning scopes may reflect shifts in research priorities or emerging challenges in the field.
  1. Traditional Antibiotic Development:
    Research centered on the development of traditional antibiotics has diminished as the focus shifts towards novel mechanisms and combination therapies to combat resistance.
  2. General Microbial Ecology Studies:
    Publications focusing solely on microbial ecology without direct implications for antimicrobial resistance or therapy have decreased, as the journal emphasizes more clinically relevant studies.
  3. Non-Clinical Trial Research:
    The frequency of publications based on non-clinical trial research, such as in vitro studies without translational significance, has waned in favor of clinical trial data and real-world evidence.
  4. Conventional Resistance Mechanisms:
    Research specifically detailing conventional resistance mechanisms (e.g., beta-lactamase production) is less prevalent as newer and more complex resistance mechanisms and their clinical implications gain attention.
  5. Basic Science without Clinical Application:
    There is a noticeable decline in basic science research that does not directly correlate with clinical applications or antimicrobial stewardship, as the journal aims to prioritize impactful research.

Similar Journals

Expert Review of Anti-Infective Therapy

Empowering Research for Healthier Futures
Publisher: TAYLOR & FRANCIS LTDISSN: 1478-7210Frequency: 12 issues/year

Expert Review of Anti-Infective Therapy, published by Taylor & Francis Ltd, is a leading journal in the field of infectious diseases, microbiology, and virology, boasting an impressive impact factor and ranking in the Q1 category across multiple disciplines. With an ISSN of 1478-7210 and E-ISSN 1744-8336, this journal has become a vital resource for researchers, professionals, and students aiming to advance their understanding of anti-infective therapies. Since its inception in 2003, the journal has provided critical insights, evidence-based reviews, and forward-thinking perspectives that contribute significantly to the ongoing efforts in combating infectious diseases. As of 2023, it ranks #36 out of 344 in Medicine/Infectious Diseases and maintains high percentiles in various other categories, reflecting its influence and reach within the scientific community. Although not an Open Access journal, its rich content is delivered through various academic libraries, sustaining its commitment to disseminating knowledge in the face of global health challenges. For those committed to innovation in the field, the Expert Review of Anti-Infective Therapy offers a platform that blends thorough research with practical applications, making significant strides in the fight against infectious pathogens.

Infectious Diseases and Therapy

Exploring the frontiers of infectious disease management.
Publisher: SPRINGER LONDON LTDISSN: 2193-8229Frequency: 4 issues/year

Infectious Diseases and Therapy is a premier scholarly journal published by Springer London Ltd, dedicated to advancing the understanding of infectious diseases through rigorous research and evidence-based therapy. With an esteemed Q1 ranking in both the Infectious Diseases and Microbiology (medical) categories, this journal is a vital resource for researchers, healthcare professionals, and students aiming to stay at the forefront of developments within the field. Launched in 2012, it has embraced an Open Access model, ensuring that groundbreaking studies and critical reviews are accessible to a global audience. Operating from its office in London, the journal encourages the dissemination of innovative therapies and diagnostic methods, fostering collaboration and knowledge sharing among the scientific community. In a landscape where infectious diseases pose significant health challenges, Infectious Diseases and Therapy stands as an essential platform for impactful research that can lead to improved healthcare outcomes worldwide.

INFECTION

Shaping the Future of Infectious Disease Research
Publisher: SPRINGER HEIDELBERGISSN: 0300-8126Frequency: 6 issues/year

INFECTION is a prestigious journal, published by Springer Heidelberg, that serves as a leading platform for the dissemination of critical research in the fields of Infectious Diseases, Microbiology, and Medicine. With an impressive Q1 ranking in multiple categories such as Infectious Diseases, Medicine (miscellaneous), and Medical Microbiology, the journal is recognized for its high-quality content and impactful contributions to the scientific community, as evidenced by its Scopus rankings placing it in the top 10th percentiles. Since its inception in 1973, and projected to continue until 2024, INFECTION has established itself as a vital resource for researchers, healthcare professionals, and students keen to explore the latest findings and advancements in infectious diseases. The journal provides a rigorous peer-review process, ensuring that only high-quality studies are published, making it an essential read for those seeking to deepen their understanding and stay abreast of the rapidly evolving landscape in infection research.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Driving Excellence in Infectious Disease Scholarship
Publisher: AMER SOC MICROBIOLOGYISSN: 0066-4804Frequency: 12 issues/year

Antimicrobial Agents and Chemotherapy, published by the American Society for Microbiology, is a leading journal in the fields of Infectious Diseases and Pharmacology. With a rich history dating back to its inception in 1963, this esteemed journal provides a vital platform for the dissemination of innovative research and advances in antimicrobials and therapeutic strategies. Currently holding a remarkable Q1 ranking in multiple categories, including Infectious Diseases and Pharmacology (medical), the journal occupies a prestigious position within its discipline, supported by exceptional rankings in Scopus metrics. As an essential resource for researchers, professionals, and students alike, it aims to foster knowledge exchange and inspire new strategies in combating infectious diseases. While not an open-access journal, it remains influential in shaping clinical applications and public health strategies through its rigorous peer-reviewed publications.

Jundishapur Journal of Microbiology

Championing the evolution of microbiological research since 2009.
Publisher: BRIEFLANDISSN: 2008-3645Frequency: 12 issues/year

Welcome to the Jundishapur Journal of Microbiology, a peer-reviewed publication dedicated to advancing the field of microbiology. Published by BRIEFLAND, this journal focuses on key areas such as infectious diseases and medical microbiology, offering a platform for researchers to share their findings from 2009 to 2024. Despite its current positioning in Quartile 4 across various categories in 2023, the journal provides a valuable resource for budding scientists and established professionals alike, contributing to the growing body of knowledge in these critical areas. While it is not an open-access journal, the Jundishapur Journal prioritizes the dissemination of research in the Netherlands, facilitating a deeper understanding of microbial science and its implications for public health. Join a community of innovators committed to exploring both emerging and established themes in microbiology.

Infectious Disease Reports

Empowering insights into the world of infectious diseases.
Publisher: MDPIISSN: Frequency: 6 issues/year

Infectious Disease Reports is a premier open-access journal published by MDPI, dedicated to advancing the field of infectious diseases. Since its inception in 2009, this journal has established itself as a significant platform for disseminating cutting-edge research, reviews, and case studies, critical for global health. With a commendable Q2 ranking in the category of Infectious Diseases and a Scopus rank of #140 out of 344, it is recognized for its impactful contributions to medical research, holding a 59th percentile in its field. The journal aims to provide comprehensive insights into various dimensions of infectious diseases, ranging from epidemiology to novel treatment modalities. As an open-access publication, Infectious Disease Reports ensures that its articles are freely available to a wide audience, fostering collaborative efforts among researchers, healthcare professionals, and students worldwide. With its ongoing commitment to excellence, the journal plays an essential role in shaping the future of infectious disease research.

JOURNAL OF INFECTION AND CHEMOTHERAPY

Elevating Standards in Infectious Disease Scholarship
Publisher: ELSEVIERISSN: 1341-321XFrequency: 6 issues/year

JOURNAL OF INFECTION AND CHEMOTHERAPY, published by Elsevier, is a leading journal in the fields of Infectious Diseases, Microbiology, and Pharmacology. With a solid reputation reflected in its prestigious Q2 ranking in Infectious Diseases and Pharmacology, and Q3 in Microbiology (medical), this journal serves as a vital resource for researchers, clinicians, and students interested in the latest advancements in the diagnosis, treatment, and prevention of infectious diseases. The journal provides a platform for high-quality, peer-reviewed scholarly articles, making it an essential reference point in the medical community. Despite being published without open access, it continues to attract significant scholarly attention, as denoted by its rankings in Scopus, which showcases its impact within the academic landscape. With a timeline converging from 1995 to 2024, JOURNAL OF INFECTION AND CHEMOTHERAPY is dedicated to advancing knowledge and contributing to better health outcomes globally.

Antibiotics-Basel

Uniting researchers to combat antibiotic resistance and promote health.
Publisher: MDPIISSN: 2079-6382Frequency: 12 issues/year

Antibiotics-Basel is a prestigious multidisciplinary journal published by MDPI, dedicated to advancing the field of antibiotic research and management. Since its inception in 2012 as an Open Access publication, the journal has established itself as a vital resource for researchers and professionals, offering an accessible platform for the dissemination of innovative findings in Biochemistry, Infectious Diseases, Microbiology, and Pharmacology. With a solid impact in its category, Antibiotics-Basel holds a Q1 ranking in critical areas such as Pharmacology and Pharmacology, Toxicology and Pharmaceutics, making it an influential journal in its field. The journal publishes high-quality research articles, reviews, and communications that are essential for advancing our understanding of antibiotic mechanisms, resistance, and therapeutic applications. Researchers are invited to submit their manuscript to contribute to this growing body of knowledge and collaborate in the fight against antibiotic resistance and infectious diseases.

Current Treatment Options in Infectious Diseases

Advancing Infectious Disease Management Through Evidence-Based Insights.
Publisher: SPRINGERNATUREISSN: Frequency: 4 issues/year

Current Treatment Options in Infectious Diseases, published by SpringerNature, is a pivotal peer-reviewed journal dedicated to advancing the field of infectious disease management and therapy. With a focus on the latest treatment modalities, this journal serves as a vital resource for researchers, healthcare professionals, and students striving to improve patient outcomes in infectious diseases. Although it is not an open-access journal, it offers valuable insights through carefully curated articles that emphasize evidence-based practices and innovative approaches in the treatment landscape. By fostering a cross-disciplinary dialogue, Current Treatment Options in Infectious Diseases aims to bridge the gap between research and clinical application, making it an essential platform for staying abreast of developments in this rapidly evolving field.

Brazilian Journal of Infectious Diseases

Transforming clinical practice with cutting-edge studies.
Publisher: ELSEVIER BRAZILISSN: 1413-8670Frequency: 6 issues/year

The Brazilian Journal of Infectious Diseases, published by Elsevier Brazil, is a premier open-access journal dedicated to advancing research and clinical practice in the field of infectious diseases. Since its inception in 2001, this journal has been pivotal in disseminating innovative studies and reviews that inform healthcare professionals and researchers alike. With an impressive impact factor reflected by its ranking in the second quartile for Infectious Diseases and third quartile for Medical Microbiology in 2023, the journal ranks #127 out of 344 in medicine – infectious diseases and #61 out of 140 in medical microbiology, showcasing its reputable standing in the scientific community. The Brazilian Journal of Infectious Diseases invites contributions that highlight significant findings, novel methodologies, and critical reviews aimed at enhancing patient care and public health initiatives. With an international readership and a focus on pressing issues in infectious diseases, it serves as an essential platform for knowledge exchange and collaboration among scholars and practitioners across Brazil and beyond. By reinforcing the importance of open access to scientific literature, this journal not only promotes transparency but also enhances the global discourse surrounding infectious diseases.